Literature DB >> 16646042

Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra.

Tristan Mirault1, David Launay, Laurence Cuisset, Eric Hachulla, Marc Lambert, Viviane Queyrel, Thomas Quemeneur, Sandrine Morell-Dubois, Pierre-Yves Hatron.   

Abstract

Muckle-Wells syndrome (MWS) is a dominantly inherited autoinflammatory disease characterized by rashes, fever, arthralgia, sensorineural deafness, and the possible development of systemic AA amyloidosis. We used anakinra to treat a 22-year-old patient with MWS who had deafness and a high serum level of C-reactive protein (CRP). Following treatment with anakinra, the patient's CRP level normalized, and she recovered from deafness. The fact that this occurrence has never been previously reported strengthens the role of anakinra in MWS but also raises new questions about the physiopathology of such deafness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16646042     DOI: 10.1002/art.21807

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease.

Authors:  Shresh Pathak; Elliot Goldofsky; Esther X Vivas; Vincent R Bonagura; Andrea Vambutas
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

Review 2.  [Cutaneous amyloidosis].

Authors:  S Schreml; R-M Szeimies; M Landthaler; P Babilas
Journal:  Hautarzt       Date:  2011-01       Impact factor: 0.751

3.  Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations.

Authors:  Neda Ahmadi; Carmen C Brewer; Christopher Zalewski; Kelly A King; John A Butman; Nicole Plass; Cailin Henderson; Raphaela Goldbach-Mansky; H Jeffrey Kim
Journal:  Otolaryngol Head Neck Surg       Date:  2011-08       Impact factor: 3.497

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 5.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

6.  The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity.

Authors:  Tammy M Martin; Zili Zhang; Paul Kurz; Carlos D Rosé; Hong Chen; Huiying Lu; Stephen R Planck; Michael P Davey; James T Rosenbaum
Journal:  Arthritis Rheum       Date:  2009-02

7.  [Recommendations on therapy using interleukin-1beta-blocking agents].

Authors:  B Manger; M Gaubitz; H Michels
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

8.  Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).

Authors:  Ori Toker; Philip J Hashkes
Journal:  Biologics       Date:  2010-05-25

Review 9.  NOD-like receptors and inflammation.

Authors:  Rebeccah J Mathews; Michael B Sprakes; Michael F McDermott
Journal:  Arthritis Res Ther       Date:  2008-11-25       Impact factor: 5.156

10.  Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).

Authors:  Leigh D Church; Sinisa Savic; Michael F McDermott
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.